PMA device
PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Ventana Medical Systems, Inc. · System, Test, Her-2/Neu, Ihc (MVC, Class III) · First FDA decision Dec 15, 2025, newest Dec 15, 2025Breast cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
22
Naming "PATHWAY anti"
MAUDE reports
1
Brand "PATHWAY anti", since 2015
PubMed studies
117
Mentioning "PATHWAY anti"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing PATHWAY anti- HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P990081-S059 · Decided Dec 15, 2025 · 122 days after receipt · Normal 180 Day Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "PATHWAY anti", any status and sponsor, newest update first.
- Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast CancerActive, not recruiting
Semmelweis UniversityAcademic, hospital or other
NCT05889390 · 71 participants · Start Feb 20, 2023 · Primary completion Oct 31, 2025
Device: Oncotherm EHY-2030 · For: HER2-negative Breast Cancer
Sites: Budapest, Hungary
21 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "PATHWAY anti", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code MVC
12 reports: 4 malfunction, 5 injury, 0 death
Newest reports for this brand
2028492-2026-03481 · Received Aug 24, 2026 · Event dated Jul 29, 2026
Device type: System, Test, Her-2/Neu, Ihc (MVC)
Device problem as coded: Incorrect, Inadequate or Imprecise Result or Readings
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2716-2011 · Started May 16, 2011 · Posted by FDA Jul 1, 2011
Reason given: The recall was initiated because Ventana Medical Systems, Inc. (Ventana), has identified the presence of precipitate in some DAB chromogen dispensers in two lots of ultraView Universal DAB Detection Kit (part number 760-500, lot A05885 and lot B00988) and one lot of iView DAB Detection Kit (part number 760-091, lot...
Cause as FDA categorized it: Pending · Device type: Immunohistochemistry Antibody Assay, Estrogen Receptor (MYA)
2 more recall records with a free account
Published research
The most relevant PubMed records for "PATHWAY anti"[tiab]. The summary above synthesizes these.
- Resistance Mechanisms to Anti-PD Cancer Immunotherapy.
Vesely MD, Zhang T, Chen L · Annu Rev Immunol · 2022Review, Research Support, Non-U.S. Gov't
- Multifunctional epiberberine mediates multi-therapeutic effects.
Liu L, Li J, He Y · Fitoterapia · 2020Review
- Paratope plasticity determines anti-HER2 (4B5) antibody specificity.
Warren PD, Landowski TH, Dodson MS, et al. · MAbs · 2025Research Support, Non-U.S. Gov't
- Prophages divert Staphylococcus aureus defenses against host lipids.
Zhou B, Pathania A, Pant D, et al. · J Lipid Res · 2024Research Support, Non-U.S. Gov't
- Role of hydrogen sulfide in cardiovascular ageing.
Testai L, Citi V, Martelli A, et al. · Pharmacol Res · 2020Research Support, Non-U.S. Gov't, Review
- The genetics and immunobiology of IgA nephropathy.
Kiryluk K, Novak J · J Clin Invest · 2014Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
Sanmamed MF, Chen L · Cell · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- New Agents for the Treatment of Advanced Bladder Cancer.
Cheetham PJ, Petrylak DP · Oncology (Williston Park) · 2016Research Support, Non-U.S. Gov't, Review
- Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study).
Vernieri F, Iannone LF, Lo Castro F, et al. · Cephalalgia · 2025Multicenter Study, Observational Study
- Potential impact of HercepTestࡊ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis.
Marszaek A, Kubicka A, Jagieo I, et al. · Pol J Pathol · 2023
- [Mechanisms and application of triptolide against breast cancer].
Li JX, Shi JF, Wu YH, et al. · Zhongguo Zhong Yao Za Zhi · 2021Review
- Inherently bioactive iron-chelating Poly (N-acryloyl 2-glycine)/chitosan hydrogel scaffolds orchestrating dual hypoxic-immune microenvironment for functional meniscus regeneration.
Xu B, Ye J, Song S, et al. · Bioact Mater · 2025
Other devices of this type
Also filed under product code MVC.
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2026
- HerceptestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Bond Oracle HER2 Ihc SystemLeica Biosystems · PMA 2014
- Hercep TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2012
- Hercap TestAgilent Technologies Singapore (International) Pte , Ltd. · PMA 2013
- Pathway Her 2 (Clone CB11)Ventana Medical Systems, Inc. · PMA 2002
- Pathway ANTI-HCR-2/NCU (4B5) Rabbit Monoclonal Primary AntibodyVentana Medical Systems, Inc. · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.